Certain patients with treatment-refractory schizophrenia may be rechallenged with clozapine following previous neutropenia. Evidence guiding patient selection and the effectiveness of lithium and granulocyte-colony stimulating factor (G-CSF) in rechallenge is limited, and factors associated with successful outcomes are unclear.
Introduction
Clozapine is an antipsychotic with unique efficacy in treatment-refractory schizophrenia 1 . In the UK, clozapine is recommended in patients who have failed to respond to trials of at least two different antipsychotics at adequate doses 2 .
However, first-line use is limited by its propensity to cause neutropenia 3 and potentially fatal agranulocytosis 4 in 3% and 0.8% of patients respectively, and regular haematological monitoring is mandatory for all patients receiving clozapine. Patients developing haematological dyscrasia are excluded from further licensed treatment.
Nonetheless, in certain individuals where illness is severe and a good response to clozapine was observed, off-label rechallenge of clozapine may be attempted after careful consideration of the risks and benefits 5 . In particular, cases where the original dyscrasia was likely to have been due to factors other than clozapine may benefit from rechallenge. Co-administration of other drugs which interact with clozapine, or in themselves cause haematological toxicity, may account for, or contribute to, some cases of neutropenia 6 . Benign ethnic neutropenia (BEN) affects 25-50% of people of African ancestry, as well those of Arabic-Middle Eastern descent 7; 8 , and has been recognised as a factor contributing to clozapine discontinuation in these populations 9 . The use of modified monitoring criteria for BEN populations 10 , co-administration of lithium 11 and G-CSF 12 have been used to augment leucocyte counts and avoid treatment interruption or discontinuation.
Due to the risk of agranulocytosis, patients and clinicians are understandably hesitant to undertake clozapine rechallenge, and it remains uncommon. The evidence base guiding practice is correspondingly sparse. The largest study consisted of 53 patients rechallenged in the UK over a five year period 13 , of whom 20 (38%) experienced a further dyscrasia, nine of which were agranulocytoses. No clear risk factors for repeat dyscrasia were identified, however the second dyscrasia was more severe, more prolonged and occurred sooner. Kanaan and Kerwin 14 studied 25 rechallenges with co-prescribed lithium, and reported that only one (4%) had a second episode of neutropenia, suggesting that lithium improved the probability of success. A systematic review 15 including the two studies mentioned above reported 112 cases of rechallenge following neutropenia of which 34 (30%) failed, and 15 rechallenges following agranulocytosis of which 12 (80%) experienced further dyscrasia.
Further evidence guiding the selection of patients for rechallenge based on their previous haematological profile is therefore needed, as is evidence regarding the utility of treatments aimed at augmenting leucocyte counts. Observational studies of clozapine rechallenge offer important insights in this regard.
The National Psychosis Unit (NPU) is a tertiary centre admitting patients from across the UK for the management of treatment-refractory schizophrenia. A significant proportion have previously discontinued clozapine due to haematological adverse events, and therefore form a unique population in which to study clozapine rechallenge. We report the outcomes of 19 adult inpatients selected for clozapine rechallenge following previous leucopenia or neutropenia, and examine whether particular clinical characteristics are associated with outcome. We focus on the efficacy, safety and tolerability of adjunctive measures including lithium and G-CSF.
Methods
All admissions to the NPU between 1 January 2007 and 31 December 2013 were screened for inclusion. Inclusion criteria comprised at least one previous episode of clozapine therapy discontinued due to concurrent leucopenia and/or neutropenia, and subsequent clozapine rechallenge on the unit. Leucopenia was defined as a white cell count (WCC) <3.0 x 10 9 /L, neutropenia as an absolute neutrophil count (ANC) <1.5 x 10 9 /L, and agranulocytosis as a ANC <0.5 x 10 9 /L. Full blood counts during treatment and, where possible, complete historical blood counts were obtained. Successful rechallenge was defined as continued clozapine therapy until discharge from the unit, and unsuccessful rechallenge being defined as recurrence of leucopenia, neutropenia or agranulocytosis prior to discharge. Blood tests during the follow up period were performed in accordance with guidelines from the clozapine monitoring service 18 (weekly for the first 18 weeks, and at four-week intervals thereafter), with the exception of those with a BEN-pattern receiving G-CSF, who had an increased frequency of monitoring (twice-weekly or on alternate days) during the initial phase of treatment, on the advice of the haematologist.
The t-test for independent and matched samples was used to compare differences in age and between and within group differences in ANC, and the Mann-Whitney and Wilcoxon signed rank test to compare treatment duration between and within groups respectively. Categorical variables were compared using the chi-square test. All reported p-values are two-sided. Statistical analysis was undertaken using SPSS 22 19 .
Results
146 patients were admitted over the study period, of whom 51 were rechallenged with clozapine. Nineteen of these patients had experienced previous clozapineassociated neutropenia that resulted in treatment discontinuation; all had primary ICD-10 diagnoses of schizophrenia. Rechallenge was successful in 15 patients (79%), and unsuccessful in four (21%) (table 1). Fourteen had undergone one previous trial of clozapine and five had undergone two previous trials, four of which were successfully rechallenged. None of the patients selected for rechallenge had previous agranulocytosis, on the basis of evidence suggesting rechallenge in this group is highly unlikely to succeed 20 *In patients with more than one previous trial, the duration between the end of the first and beginning of the most recent trials are reported. ** Follow up is defined as time from re-initiation of clozapine until discharge from the ward, or to recurrence of neutropenia.
Unsuccessful rechallenge
All four unsuccessful rechallenges had pre-treatment ANC consistently above 2 x 10 9 /L, thus not meeting criteria for benign neutropenia, and all developed neutropenia below 1.0 x10 9 /L on rechallenge, and one developed agranulocytosis ( The remaining 2/15 (13%) successfully rechallenged patients were White, and did not have an ANC at baseline consistent with chronic neutropenia. Both were prescribed lithium. One patient had a sustained drop in baseline ANC four weeks after clozapine initiation, as shown in figure 1d .
Additional co-prescribed medications in the 10 patients without BEN were lamotrigine (n = 2), valproate (n = 3), amisulpride (n = 2) and aripiprazole (n = 1). Of these, lamotrigine and valproate are associated with neutropenia. 1d: White patient who developed a drop in mean ANC four weeks after commencing clozapine but was able to continue treatment with lithium and a single administration of G-CSF.
Discussion
In this the third largest series of clozapine rechallenge in adults, we have shown that in a selected group of inpatients with severe treatment refractory illness, 15/19 (79%) of patients were successfully re-established on clozapine following previous treatment-emergent leucopenia or neutropenia. This is higher than that of Dunk and colleagues 13 reporting successful rechallenge in 62% (32/52), and comparable to the 24/25 (96%) success rate reported previously by our unit 14 . We believe this demonstrates the importance of carefully selecting patients who have a relatively reduced risk of a neutropenia based on their previous history, and optimising rechallenge with adjunctive treatments.
The mechanisms of clozapine-induced neutropenia and agranulocytosis remain uncertain 21 . There may exist a unitary process, where neutropenia progresses inevitably to agranulocytosis if clozapine is not terminated 21 . An alternative hypothesis posits two distinct mechanisms, one leading to agranulocytosis, and another to persistent neutropenia but not agranulocytosis 6 .
Given that the haematological outcomes on rechallenge are likely to reflect the cause underlying discontinuation in earlier trials, we hypothesise the following categories based on the rechallenge outcomes observed in our cohort: 1) clozapine-induced agranulocytosis, or neutropenia that would otherwise have progressed to agranulocytosis, with a characteristic pattern and time-course; 2) persistent neutropenia that does not progress to agranulocytosis that may be related to clozapine but also the co-prescription of other agents, and 3) idiopathic, persistent neutropenia (not restricted to those with ethnicity associated with BEN) unrelated to clozapine or other agents. We suggest that groups 2 and 3 can be considered for rechallenge with specialist input.
Factors associated with unsuccessful rechallenge
Consistent with established findings that age is a risk factor for clozapine-induced dyscrasia 3; 4 , patients who developed neutropenia on rechallenge were significantly older. Similar to the finding by Dunk et al 13 , patients who failed rechallenge had a more severe and rapid onset of subsequent neutropenia, suggesting an immunemediated mechanism.
Three out of four patients developing neutropenia on rechallenge showed a spike in ANC in the fortnight preceding dyscrasia, a phenomenon which was found to be a sensitive but non-specific predictor of agranulocytosis 22 . A possible mechanism is the production of endogenous granulopoeitic factors that initially compensates for the incipient fall in granulocytes. The response to G-CSF was attenuated in two patients who failed rechallenge, in comparison to BEN patients whose granulopoietic response did not diminish despite successive administrations or G-CSF. This suggests that attenuation in response to G-CSF is an indicator of injury to the granulocyte precursors in the bone marrow, and that clozapine should be discontinued immediately.
Factors associated with successful rechallenge
Successful rechallenge was associated with a shorter median duration of first exposure to clozapine: one explanation might be that these patients failed their first trial early in treatment due to constitutionally low neutrophils, and not clozapine toxicity. Over half of the successfully rechallenged patients were White, and therefore ineligible for BEN criteria, but nonetheless had consistently low preclozapine ANC. This is consistent with previous studies 9 that suggest ANCs at the lower end of the population distribution in otherwise asymptomatic individuals is a common reason for clozapine discontinuation, and does not necessarily indicate clozapine toxicity. Therefore, correctly identifying this haematological pattern is critical in selecting patients who are likely to be successfully rechallenged. Four out of five patients who had undergone more than one previous trial were successfully rechallenged, suggesting that multiple trials are not necessarily associated with unsuccessful rechallenge.
Treatment with lithium and G-CSF
All of the patients who developed neutropenia on rechallenge were prescribed lithium, suggesting that, in these patients, it does not protect against clozapineinduced neutropenia. Similarly, responses to G-CSF were attenuated in patients who failed rechallenge, also arguing that G-CSF is not protective against clozapineinduced neutropenia in these patients.
Of the successful rechallenges, 4/5 of the BEN patients and 8/10 of the remaining patients received lithium, suggesting that lithium has utility in increasing ANC and avoiding treatment discontinuation. Two BEN patients received regular G-CSF, and three White patients received single doses of G-CSF, indicating that G-CSF can also play a role in facilitating uninterrupted treatment with clozapine.
However, lithium may compromise neutrophil function 23; 24 , and no studies have investigated the rate of infection in lithium treatment. Furthermore, the use of G-CSF in allowing continued clozapine therapy is contentious. In addition to commonly reported acute side-effects such as bone pain 25 in patients receiving G-CSF following chemotherapy, the safety of long-term treatment with G-CSF is unknown.
Osteopenia 26 and splenic enlargement 27 have been described, and we recommend monitoring of bone density and spleen size in long-term G-CSF use.
Implications for clinical practice and future research
Our findings suggest that current concepts of BEN are too narrow, and leads to unnecessary discontinuation of clozapine in those with a picture of idiopathic neutropenia. ANCs of 0.5 -1.5 x 10 9 /L, defined haematologically as 'mild to moderate neutropenia' are not associated with a significantly increased risk of infection 28 . Consideration should therefore be given the use of lowered thresholds to patients of other ethnicities, following haematological evaluation. The use of definitions such as chronic idiopathic neutropenia 29 may aid this process. Future approaches to differentiating clozapine-induced neutropenia from incidental neutropenia unrelated to clozapine may include consideration of dynamic trends in ANC relative to an individual's baseline pre-clozapine ANC, rather than the absolute counts relative to an arbitrary threshold.
We could not clearly identify a subset of patients who develop a milder form of clozapine-induced neutropenia, although the trend in one case (figure 1d ) did support the existence of such a pattern. Further work is necessary to identify whether clozapine can cause a milder neutropenia, or induces fluctuations in ANC.
Where possible, other drugs associated with neutropenia were stopped prior to rechallenge. However, 3/4 (75%) patients failing rechallenge were co-prescribed valproate, compared to 3/15 (20%) who were successfully rechallenged. Clozapine in combination with valproate has been associated with a greater risk of neutropenia than with either drug alone 30 
Limitations
Clozapine rechallenge is a rare occurrence, and the small number of cases reported here reflects this. The statistical analyses and conclusions in relation to the unsuccessful rechallenge group should therefore be interpreted with caution. A further limitation of this study arises from its retrospective observational design.
Follow-up ended when patients were discharged from the service, with a median duration of follow-up in successfully rechallenged patients of 41 weeks. It is therefore possible that some of these individuals developed neutropenia after discharge. However, other rechallenge studies with longer follow-up found a median time to dyscrasia of 5.5 weeks 13 , suggesting that most dyscrasia occurs soon after restarting clozapine.
The severity of psychosis in our patient group did not permit a drug-free period prior to clozapine initiation. Therefore, other antipsychotics associated with neutropenia such as olanzapine and risperidone 6 may have contributed to the persistent preclozapine neutropenia observed in some patients. It remains extremely difficult to demonstrate that a given drug contributes to dyscrasia when prescribed in conjunction with clozapine, and case reports have been conflicting 36 .
The highly selected patient group and setting may limit the generalizability of our findings; patients with BEN or other benign neutropenia may be over-represented in our sample, and not all centres will have experience in using G-CSF. Definitions of ethnic groups are imprecise 37 , and the categories used in this study overlook the significant diversity that exist within populations.
Clinical points
• Neutropenia is a frequent reason for discontinuing clozapine, and there is often uncertainty over attempting rechallenge.
• This study suggests that with careful selection and support from a haematologist, some patients can be successfully rechallenged following neutropenia.
• Look carefully at circumstances of initial neutropenia. Consider whether benign ethnic neutropenia (BEN), co-prescribed medications and medical conditions could have been responsible.
• In cases of BEN, lithium and G-CSF may aid rechallenge. White patients can also present with a picture of persistent neutropenia identical to BEN.
